Concepedia

The Inhibitory Effect of CD46, CD55, and CD59 on Complement Activation After Immunotherapeutic Treatment of Cervical Carcinoma Cells with Monoclonal Antibodies or Bispecific Monoclonal Antibodies

Kyra A. Gelderman, V.T. Blok, Gert Jan Fleuren, Arko Gorter

Laboratory Investigation · 2002 · 77 citations · 40 references

DOI

Concepts

References

40

Cancer statistics, 1994

C. C. Boring, T. S. Squires, T. Tong et al. · CA A Cancer Journal for Clinicians · 1994 · 1.3K citations · Full text

, , +4

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

G. Riethmüller, E Holz, Günter Schlimok et al. · Journal of Clinical Oncology · 1998 · 516 citations

Monoclonal antibody G 250 recognizes a determinant present in renal‐cell carcinoma and absent from normal kidney

E. Oosterwdk, D. J. Ruiter, Ph. J. Hoedemaeker et al. · International Journal of Cancer · 1986 · 365 citations

Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids.

M. Edward Medof, E I Walter, Joanne L. Rutgers et al. · The Journal of Experimental Medicine · 1987 · 339 citations · Full text

, , +25

MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas

Hirotsugu Uemura, Yasuaki Nakagawa, Koichi Yoshida et al. · British Journal of Cancer · 1999 · 157 citations · Full text